SynthesisJournal of infection and public health2020
An overview of the safety, clinical application and antiviral research of the COVID-19 therapeutics.
Synthesis in Journal of infection and public health, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 1 synthesis or guideline pooled it.
- A Systematic Review of the Global Intervention for SARS-CoV-2 Combating: From Drugs Repurposing to Molnupiravir Approval.Drug design, development and therapy · 2022Pooled it
- Mechanistic insights into the impact of prenatal viral infections on maternal and offspring immunity.Npj viruses · 2026Review
- Risk assessment for cardiovascular adverse drug events in the ICU: Case study on COVID-19 patients.PloS one · 2026Article
- Global research hotspots, trends, and future directions of ivermectin research: an informatics investigation (2020-2025).Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Clinical characteristics of SARS-CoV-2 infection in patients with chronic hepatitis B during interferon antiviral therapy.Biosafety and health · 2025Article
- Navigating the COVID-19 Therapeutic Landscape: Unveiling Novel Perspectives on FDA-Approved Medications, Vaccination Targets, and Emerging Novel Strategies.Molecules (Basel, Switzerland) · 2024Review
- Indole-Based Compounds as Potential Drug Candidates for SARS-CoV-2.Molecules (Basel, Switzerland) · 2023Review
- Evaluation interaction of graphene oxide with heparin for antiviral blockade: a study of ab initio simulations, molecular docking, and experimental analysis.Journal of molecular modeling · 2023Article
- TMPRSS2 Inhibitor Discovery Facilitated through anACS medicinal chemistry letters · 2023Article
- Repositioned Natural Compounds and Nanoformulations: A Promising Combination to Counteract Cell Damage and Inflammation in Respiratory Viral Infections.Molecules (Basel, Switzerland) · 2023Review
- An overview on the treatments and prevention against COVID-19.Virology journal · 2023Review
- regCOVID: Tracking publications of registered COVID-19 studies.BMC medical research methodology · 2022Article
- Inhibition of SARS-CoV-2 pathogenesis by potent peptides designed by the mutation of ACE2 binding region.Computers in biology and medicine · 2022Article
- Peptide candidates for the development of therapeutics and vaccines against β-coronavirus infection.Bioengineered · 2022Review
- Molecular docking and molecular dynamics study Lianhua Qingwen granules (LHQW) treats COVID-19 by inhibiting inflammatory response and regulating cell survival.Frontiers in cellular and infection microbiology · 2022Article
- Nanomaterials as Promising Theranostic Tools in Nanomedicine and Their Applications in Clinical Disease Diagnosis and Treatment.Nanomaterials (Basel, Switzerland) · 2021Review
- The mechanisms and clinical application of Traditional Chinese Medicine Lianhua-Qingwen capsule.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2021Review
- Predictors of incident SARS-CoV-2 infections in an international prospective cohort study.BMJ open · 2021Article
- Virtual screening of plant-derived compounds against SARS-CoV-2 viral proteins using computational tools.The Science of the total environment · 2021Article
- Review on therapeutic targets for COVID-19: insights from cytokine storm.Postgraduate medical journal · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Since a novel coronavirus pneumonia outbreak in late December 2019, coronavirus disease -19 (COVID-19) epidemic has gradually spread worldwide, becoming a major public health event. No specific antivirals are currently available for COVID-19 caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The treatments for COVID-19 are mainly based on the experiences of similar virus such SARS-CoV, MERS-CoV, HIV and influenza viruses. Scientists have taken great efforts to investigate the effective methods for the treatment of COVID-19. Up to now, there are over 1000 clinical studies for COVID-19 all over the world. In this article, we reviewed the current options for COVID-19 therapy including small molecules such as Remdesivir, Favipiravir, Lopinavir/Ritonavir etc, peptide inhibitors of ACE2, Traditional Chinese Medicines and Biologics such as SARS-CoV-2-specific neutralizing antibodies, mesenchymal stem cells and vaccines etc. Meanwhile, we systematically reviewed their clinical safety, clinical applications and progress of antiviral researches. The therapeutic effect of these antiviral drugs is summarized and compared, hoping to provide some ideas for clinical options of COVID-19 treatment and also provide experiences for the life-threatening virus diseases in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.